Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis

Author:

Park Taehwan1ORCID,Hwang Monica1

Affiliation:

1. Pharmacy Administration and Public Health, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA

Publisher

Informa UK Limited

Reference31 articles.

1. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

2. American Heart Association. Cardiovascular disease: a costly burden for America – projections through 2035. Washington (DC): The American heart association office of federal advocacy; 2017.

3. Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016

4. Cardiovascular disease and diabetes [Internet]. Dallas (TX): American Heart Association; [cited 2023 Sep 7]. Available from: https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-risks/cardiovascular-disease–diabetes

5. New drugs at FDA: CDER’s new molecular entities and new therapeutic biological products [Internet]. Silver Spring (MD): US Food & Drug Administration; [cited 2023 Sep 7]. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3